Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.

Trastuzumab deruxtecan was also recently Food and Drug Administration (FDA) approved for non-small cell lung cancer with  HER2  mutations.

Lung cancer patients that completed at least one ePROM questionnaire within 6 weeks of their first visit to the cancer centre (baseline), between February 2019 and February 2020, were included in the study.

Objective The aim of this study was to compare the efficacy and toxicity of checkpoint inhibitors between RCTs and RWE studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma.

US research suggests that the expansion of the US Preventive Services Taskforce eligibility criteria for lung cancer screening in 2021 may be helping to lessen racial disparities in the uptake of screening.

Authors: Ana Ortega-Franco & Shereen Rafee Abstract The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorithm of this subset of patients almost two decades ago.

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology .

Keam  Abstract Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated for extensive-stage small cell lung cancer (ES-SCLC).

DOI [Teaser] Key Summary Points Non-small cell lung cancer (NSCLC) patients with and without response to PD-I immunotherapy have different diversity and composition of gut microbiota.

Authors: Monia Sisi, Michele Fusaroli, Andrea De Giglio, Francesco Facchinetti, Andrea Ardizzoni, Emanuel Raschi & Francesco Gelsomino Abstract Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC).

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.

Statistical cure of lung cancer occurs around 10 years after diagnosis.

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies.

DOI [Teaser] Key Summary Points Treatment with immune checkpoint inhibitors is generally poorly effective for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients who experience acquired resistance to an EGFR-tyrosine kinase inhibitor (TKI).

DOI [Teaser] Key Points for Decision Makers The dominant approaches to modeling the cost effectiveness of immuno-oncology (IO) therapies in advanced non-small cell lung cancer are Markov and partitioned survival models.

Davis, Parisa Karimi, William Sawyer, Ning Yu, Aliki Taylor & Josephine Feliciano Abstract Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line (1L) therapy for EGFR mutation-positive (EGFRm) advanced/metastatic non-small cell lung cancer (NSCLC).

A quick guide to the JAVELIN clinical trials investigating the efficacy and safety of the PD-L1 inhibitor avelumab in the lung cancer setting.

The US Preventive Services Task Force has updated its recommendations for lung cancer screening with low-dose computed tomography among current and former smokers.